Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

被引：0
|
作者：
Jinlin Song
Qiufei Ma
Wei Gao
Ze Cong
Jipan Xie
Zachary Zimmerman
Laura Belton
Janet Franklin
Stephen Palmer
机构：
[1] Analysis Group,
[2] Inc.,undefined
[3] Amgen Inc.,undefined
[4] Analysis Group,undefined
[5] Inc.,undefined
[6] LB Biostatistics,undefined
[7] Centre for Health Economics,undefined
[8] University of York,undefined
来源：
Advances in Therapy | 2019年 / 36卷
关键词：
Blinatumomab; Complete remission; Inotuzumab ozogamicin; Matching-adjusted indirect comparison; Overall survival; Relapsed or refractory acute lymphoblastic leukemia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：950 / 961
页数：11
相关论文
共 50 条
  • [1] Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Song, Jinlin
    Ma, Qiufei
    Gao, Wei
    Cong, Ze
    Xie, Jipan
    Zimmerman, Zachary
    Belton, Laura
    Franklin, Janet
    Palmer, Stephen
    ADVANCES IN THERAPY, 2019, 36 (04) : 950 - 961
  • [2] Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
    Irina Proskorovsky
    Yun Su
    Kyle Fahrbach
    Erik Vandendries
    Véronique Pagé
    Uchenna Onyekwere
    Yunyang Wang
    Joseph C. Cappelleri
    Matthias Stelljes
    Advances in Therapy, 2019, 36 : 2147 - 2160
  • [3] Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
    Proskorovsky, Irina
    Su, Yun
    Fahrbach, Kyle
    Vandendries, Erik
    Page, Veronique
    Onyekwere, Uchenna
    Wang, Yunyang
    Cappelleri, Joseph C.
    Stelljes, Matthias
    ADVANCES IN THERAPY, 2019, 36 (08) : 2147 - 2160
  • [4] Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
    Proskorovsky, Irina
    Vandendries, Erik
    Page, Veronique
    Cappelleri, Joseph C.
    Stelljes, Matthias
    ADVANCES IN THERAPY, 2020, 37 (02) : 958 - 962
  • [5] Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL)
    Stelljes, Matthias
    Su, Yun
    Fahrbach, Kyle
    Vandendries, Erik
    Page, Veronique
    Onyekwere, Uchenna
    Wang, Yunyang
    Cappelleri, Joseph C.
    Proskorovsky, Irina
    BLOOD, 2017, 130
  • [6] Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
    Irina Proskorovsky
    Erik Vandendries
    Véronique Pagé
    Joseph C. Cappelleri
    Matthias Stelljes
    Advances in Therapy, 2020, 37 : 958 - 962
  • [7] Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
    Ueda, Tomoaki
    Fukushima, Kentaro
    Kusakabe, Shinsuke
    Yoshida, Koki
    Suga, Makiko
    Nakai, Ritsuko
    Koike, Midori
    Hino, Akihisa
    Akuta, Keigo
    Toda, Jun
    Nagate, Yasuhiro
    Doi, Yukiko
    Fujita, Jiro
    Yokota, Takafumi
    Hosen, Naoki
    LEUKEMIA RESEARCH REPORTS, 2022, 17
  • [8] Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia
    George, Binsah
    Kantarjian, Hagop
    Jabbour, Elias
    Jain, Nitin
    IMMUNOTHERAPY, 2016, 8 (02) : 135 - 143
  • [9] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
    Deepa Bhojwani
    Richard Sposto
    Nirali N. Shah
    Vilmarie Rodriguez
    Constance Yuan
    Maryalice Stetler-Stevenson
    Maureen M. O’Brien
    Jennifer L. McNeer
    Amrana Quereshi
    Aurelie Cabannes
    Paul Schlegel
    Claudia Rossig
    Luciano Dalla-Pozza
    Keith August
    Sarah Alexander
    Jean-Pierre Bourquin
    Michel Zwaan
    Elizabeth A. Raetz
    Mignon L. Loh
    Susan R. Rheingold
    Leukemia, 2019, 33 : 884 - 892
  • [10] Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
    Verneris, Michael R.
    Ma, Qiufei
    Zhang, Jie
    Keating, Amy
    Tiwari, Ranjan
    Li, Junlong
    Yang, Hongbo
    Agarwal, Abhijit
    Pacaud, Lida
    BLOOD ADVANCES, 2021, 5 (23) : 5387 - 5395
12345